View Future GrowthMarvel Biosciences 과거 순이익 실적과거 기준 점검 0/6Marvel Biosciences의 연간 평균 수익은 6.9%였으며, Biotechs 산업의 수익은 연간 33.8% 증가했습니다.핵심 정보6.94%순이익 성장률29.93%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Jan 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.공시 • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.공시 • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.공시 • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.공시 • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering공시 • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.공시 • Nov 25Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025.공시 • Oct 13Marvel Biosciences Shares Positive Results of Mb204 in the Oprm1 Model of AutismMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel reported that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model. Key Highlights: A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others. A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response. The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro- social effect. Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide.공시 • May 17Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement of up to 10,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 1,000,000 on May 16, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.15 per share on the date that is two years from the date of the issuance. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering payable in cash, plus finder’s warrants in an amount equal to up to 7% of the aggregate number of Units, with each Finder’s Warrant being exercisable to acquire one common share at a price of CAD 0.15 per share until two years following the issuance of the Finder’s Warrants. The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus one day from the issuance of the Units and such other restrictions as imposed under applicable securities legislation. The Offering is subject to acceptance by the TSX Venture Exchange.공시 • Jan 21Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it has issued unsecured convertible debentures for the gross proceeds of CAD 500,000 on January 19, 2024. The Debentures will mature 3 years following the date of issuance and will bear interest at a rate of twelve percent 12% per annum , payable annually in arrears. Interest may be repaid in cash or common shares, at the option of the company, based on the 20-day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least CAD 0.60 per share for a period of 10 consecutive trading days, at any time during the term of the debentures, the company shall have the right, at its discretion, to require the holder of the debentures to convert the outstanding principal amount into common shares at the conversion price. The company did not pay any commission, finder’s fee, or similar payment in connection with the offering. Pursuant to applicable Canadian securities laws, the debentures, as well as any underlying common shares to be issued upon conversion or exchange of these securities, are subject to a hold period of four months and one day. The Private Placement remains subject to the final approval of the TSX Venture Exchange.공시 • Oct 28Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024.공시 • Aug 23Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human TrialsMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.매출 및 비용 세부 내역Marvel Biosciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:MBCO.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Jan 260-21031 Oct 250-21131 Jul 250-21130 Apr 250-21031 Jan 250-21031 Oct 240-11031 Jul 240-21030 Apr 240-21131 Jan 240-31131 Oct 230-31131 Jul 230-21130 Apr 230-21031 Jan 230-21031 Oct 220-21131 Jul 220-31130 Apr 220-41131 Jan 220-41131 Oct 210-31131 Jul 210-31130 Apr 210-11131 Jan 210-11031 Oct 200-11031 Jul 200-110양질의 수익: MBCO.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: MBCO.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: MBCO.F는 수익성이 없지만 지난 5년 동안 연평균 6.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 MBCO.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: MBCO.F은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: MBCO.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 07:25종가2026/05/21 00:00수익2026/01/31연간 수익2025/07/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Marvel Biosciences Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 18Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingOn April 17, 2026, Marvel Biosciences Corp closed the transaction.
공시 • Apr 17Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental DisordersMarvel Biosciences Corp., and its wholly-owned subsidiary, Marvel Biotechnology Inc. announced it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204. This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess: Well accepted clinic ready excipients; A high concentration/low volume dosing solution; A simple, economic manufacturing process; Long term stability at room temperature; High oral bioavailability. Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism pre-clinical studies. We actually achieved 79 and 91% oral bioavailability (F%), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our Phase I trial, but also builds additional intellectual property around MB-204. The identification of a pediatric-friendly liquid formulation is another milestone in Marvel’s development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the Company’s intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel’s transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.
공시 • Dec 08Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026Marvel Biosciences Corp., Annual General Meeting, Feb 10, 2026.
공시 • May 13Marvel Biosciences Corp. announced that it has received CAD 1.01875 million in fundingOn May 12, 2025. Marvel Biosciences Corp. has closed the transaction. It has issued 8,150,000 units at a price of CAD 0.125 per Unit for aggregate gross proceeds of CAD 1,018,750.
공시 • Mar 29Marvel Biosciences Corp. announced that it expects to receive CAD 1.5 million in fundingMarvel Biosciences Corp. announces a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.125 per unit for gross proceeds of CAD 1,500,000 on March 28, 2025. Each Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.175 per share. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering
공시 • Jan 08Marvel Biosciences Corp. announced that it expects to receive CAD 2.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it will issue up to 16,666,667 common shares of the company at a price of CAD 0.15 per common share for the gross proceeds of up to CAD 2,500,000.05 on January 7, 2025. The closing of the offering may occur in one or more tranches, the first of which is expected to close on or about February 14, 2025. The closing of the offering is subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. The securities offered under the listed issuer financing exemption will not be subject to a hold period, pursuant to applicable Canadian securities laws.
공시 • Nov 25Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025Marvel Biosciences Corp., Annual General Meeting, Jan 15, 2025.
공시 • Oct 13Marvel Biosciences Shares Positive Results of Mb204 in the Oprm1 Model of AutismMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel reported that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social behaviour deficits typically seen in the model. Key Highlights: A high dose of MB204 (2.5 mg/kg) significantly restored social behaviour in all measured endpoints (p<0.0001). Improvements were seen in social interaction behaviours including, the number and duration of nose contacts, the number and duration of paw contacts, and time spent self-grooming, amongst others. A lower dose of MB204 (1 mg/kg) also reversed nearly all social behaviour deficits, showing a clear connection between dose and response. The higher dose of MB204 not only improved/restored social interactions in Oprm1 (autistic) mice, but even outperformed the social interactions of normal (non-autistic) mice on several endpoints, demonstrating MB204's potent pro- social effect. Currently, Drs. Le Merrer and Becker are now testing MB204 in another chronic Rett syndrome model (Mecp2) and are looking forward to seeing how it performs 'head-to-head' against the approved drug Trofinetide.
공시 • May 17Marvel Biosciences Corp. announced that it expects to receive CAD 1 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement of up to 10,000,000 units at a price of CAD 0.10 per unit for the gross proceeds of CAD 1,000,000 on May 16, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD 0.15 per share on the date that is two years from the date of the issuance. In connection with the Offering, the Company may pay a finder’s fee in connection with the issue and sale of any or all of the Units under the Offering. The Finder’s Fee shall consist of a payment of up to 7% of the gross proceeds of the Offering payable in cash, plus finder’s warrants in an amount equal to up to 7% of the aggregate number of Units, with each Finder’s Warrant being exercisable to acquire one common share at a price of CAD 0.15 per share until two years following the issuance of the Finder’s Warrants. The Common Shares and the Warrants are subject to a hold period and resale restriction in Canada that expires four months plus one day from the issuance of the Units and such other restrictions as imposed under applicable securities legislation. The Offering is subject to acceptance by the TSX Venture Exchange.
공시 • Jan 21Marvel Biosciences Corp. announced that it has received CAD 0.5 million in fundingMarvel Biosciences Corp. announced a non-brokered private placement that it has issued unsecured convertible debentures for the gross proceeds of CAD 500,000 on January 19, 2024. The Debentures will mature 3 years following the date of issuance and will bear interest at a rate of twelve percent 12% per annum , payable annually in arrears. Interest may be repaid in cash or common shares, at the option of the company, based on the 20-day volume weighted average trading price of the common shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange. In the event that the volume weighted average trading price of the common shares on the TSX Venture Exchange is at least CAD 0.60 per share for a period of 10 consecutive trading days, at any time during the term of the debentures, the company shall have the right, at its discretion, to require the holder of the debentures to convert the outstanding principal amount into common shares at the conversion price. The company did not pay any commission, finder’s fee, or similar payment in connection with the offering. Pursuant to applicable Canadian securities laws, the debentures, as well as any underlying common shares to be issued upon conversion or exchange of these securities, are subject to a hold period of four months and one day. The Private Placement remains subject to the final approval of the TSX Venture Exchange.
공시 • Oct 28Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024Marvel Biosciences Corp., Annual General Meeting, Jan 09, 2024.
공시 • Aug 23Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human TrialsMarvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that it has successfully completed its 4-week good laboratory practice (GLP), FDA investigational new drug (IND), dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.